- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 889
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan Clear all
- Conditions
- Prostate Adenocarcinoma
- Interventions
- C-11 choline PET tracer, Gadobutrol, PET/MR scanner
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
- Interventions
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI, Quality of Life Questionnaires
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Rhabdomyosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more
- Conditions
- Alzheimer Disease, Cognitive Decline
- Interventions
- [18F]AV-1451, Positron Emission Tomography
- Drug · Procedure
- Lead sponsor
- Neil M Rofsky, MD, MHA
- Other
- Eligibility
- 38 Years to 96 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Ibrutinib, Positron Emission Tomography
- Procedure · Biological · Drug
- Lead sponsor
- Yazeed Sawalha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Columbus, Ohio • Richmond, Virginia
- Conditions
- Solid Tumors
- Interventions
- PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 479
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
- Interventions
- 68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography
- Drug · Procedure
- Lead sponsor
- Dana Mathews
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- 18F-Fluoromisonidazole, Carboplatin, Computed Tomography, External Beam Radiation Therapy, Fludeoxyglucose F-18, Image-Guided Adaptive Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Positron Emission Tomography
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 29
- States / cities
- Palo Alto, California • Augusta, Georgia • Chicago, Illinois + 23 more
- Conditions
- Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Recurrent Adult Brain Tumor, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilomyxoid Astrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligoastrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Cerebellar Astrocytoma, Untreated Childhood Cerebral Astrocytoma, Untreated Childhood Diffuse Astrocytoma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Gemistocytic Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligoastrocytoma, Untreated Childhood Oligodendroglioma, Untreated Childhood Pilomyxoid Astrocytoma, Untreated Childhood Protoplasmic Astrocytoma, Untreated Childhood Subependymal Giant Cell Astrocytoma, Untreated Childhood Visual Pathway and Hypothalamic Glioma, Untreated Childhood Visual Pathway Glioma
- Interventions
- 18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT), Magnetic resonance imaging
- Drug · Procedure
- Lead sponsor
- Erik Mittra
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Meningioma
- Interventions
- Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder, Healthy
- Interventions
- 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor, PET Scan
- Drug · Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Positron Emission Tomography, Lymphadenectomy, Radiation Therapy, Abiraterone Acetate, Prednisone, Computed Tomography, Abiraterone, PSMA PET Scan
- Procedure · Radiation · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2037
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cannabis Use Disorder, Healthy
- Interventions
- [11C]APP311
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cancer, Coronary Artery Disease
- Interventions
- PET-MR imaging on Biograph mMR scanner, MR-only imaging on Biograph mMR scanner, MR imaging on the Siemens Vida 3T MR scanner
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2040
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
- Interventions
- Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Docetaxel, Esophagectomy, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2036
- U.S. locations
- 96
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Alzheimer Disease
- Interventions
- UCB-J, MRI Scan, PET Scan
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 75 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 176
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
- Conditions
- Bladder Cancer
- Interventions
- Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- Lawrence Fong
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Enzalutamide, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- High Risk Prostate Carcinoma, Prostate Cancer
- Interventions
- Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Ivan de Kouchkovsky, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Normal Physiology, Opioid Use Disorders
- Interventions
- [11C]raclopride plus placebo, [11C]raclopride plus drug, [11C]NNC-112
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland